Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 10/20 | 0.57 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | MC5R | P33032 | 1/20 | 0.56 |
| ▸ | MC3R | P41968 | 1/20 | 0.56 |
| ▸ | MC1R | Q01726 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CTSH | P09668 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31265190 | 0.94 | C5AR1 (0.61) | C5AR1CXCL8MC4RMC5RMC3R | |
| SCHEMBL30439204 | 0.90 | C5AR1 (0.66) | C5AR1CXCL8MC4RMC5RMC3R | |
| SCHEMBL30367722 | 0.88 | OPRM1 (0.60) | C5AR1OPRM1OPRD1 | |
| SCHEMBL26426326 | 0.88 | CTSL (0.65) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL25665363 | 0.88 | CTSL (0.69) | C5AR1CXCL8MC4RMC5RMC3R | |
| SCHEMBL30355006 | 0.87 | C5AR1 (0.64) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL31053728 | 0.87 | KISS1R (0.56) | C5AR1CXCL8CTSLCTSSCTSK | |
| SCHEMBL25664212 | 0.86 | CTSL (0.68) | C5AR1CXCL8MC4RMC5RMC3R | |
| SCHEMBL31127566 | 0.86 | OPRM1 (0.60) | C5AR1OPRM1OPRD1 | |
| SCHEMBL30675106 | 0.86 | CTSL (0.59) | C5AR1CXCL8CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242039-A1 | TOXIN-DERIVED DELIVERY CONSTRUCTS | THORNHILL THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240299565-A1 | TOXIN-DERIVED DELIVERY CONSTRUCTS | APPLIED MOLECULAR TRANSPORT INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4316586-A2 | TOXIN-DERIVED DELIVERY CONSTRUCTS FOR ORAL DELIVERY | Applied Molecular Transport Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4082558-B1 | TOXIN-DERIVED DELIVERY CONSTRUCTS FOR ORAL DELIVERY | APPLIED MOLECULAR TRANSPORT INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230158163-A1 | TOXIN-DERIVED DELIVERY CONSTRUCTS | THORNHILL THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4082558-A1 | TOXIN-DERIVED DELIVERY CONSTRUCTS FOR ORAL DELIVERY | Applied Molecular Transport Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11426466-B2 | Toxin-derived delivery constructs for pulmonary delivery | APPLIED MOLECULAR TRANSPORT INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3762009-B1 | TOXIN-DERIVED DELIVERY CONSTRUCTS FOR ORAL DELIVERY | APPLIED MOLECULAR TRANSPORT INC (US) | 2022-05-11 | — | — | EP | disclosed |